Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

Item

http://www.wikidata.org/entity/Q38102892

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

@en

type

Item

label

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

@en

prefLabel

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

@en

P1476

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma

@en

P2093

Ade Olujohungbe

http://www.w3.org/2001/XMLSchema#string

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Darrell White

http://www.w3.org/2001/XMLSchema#string

Donna Reece

http://www.w3.org/2001/XMLSchema#string

Faraz Zaman

http://www.w3.org/2001/XMLSchema#string

Kevin Song

http://www.w3.org/2001/XMLSchema#string

Khalid Mezzi

http://www.w3.org/2001/XMLSchema#string

Richard LeBlanc

http://www.w3.org/2001/XMLSchema#string

P2860

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

Lenalidomide after stem-cell transplantation for multiple myeloma

IMWG consensus on maintenance therapy in multiple myeloma.

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.

Management of multiple myeloma: the changing landscape.

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.

Gastroesophageal reflux and asthma in children: a systematic review.

P304

611-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0384

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23628980

http://www.w3.org/2001/XMLSchema#string

P932

3662853

http://www.w3.org/2001/XMLSchema#string